Bifogade filer
PDF
Beskrivning
| Land | Finland |
|---|---|
| Lista | Spotlight |
| Sektor | Handel & varor |
| Industri | Detaljhandel |
In an update from its June 27, 2024, press release, Eevia Health Plc ("Eevia" or "the Company") announces that it is signing a Term Sheet Agreement with the International Partner for a Global Supply Agreement of a nutraceutical ingredient.
For immediate release
Seinäjoki, Finland 12.02.2025
The International Partner is part of a corporation with over €36 billion in revenue and more than 66,000 employees. On October 17, 2023, Eevia signed an NDA with the Partner. Since then, they have collaborated on a feasibility study and a global supply arrangement for a nutraceutical extract. The Partner has conducted a safety and regulatory audit, including analytical work and toxicology studies, confirming the ingredient's safety. Eevia has produced multiple industrial-scale batches and provides technical and scientific support. Eevia has a clinical study on the product.
Eevia and the Partner is entering a Term Sheet Agreement (TSA) to outline the terms for an exclusive Purchase Agreement, set to be finalized in the coming months. The TSA defines commercial terms, including sales volumes, and will be accompanied by a Quality Agreement. Through the global Purchase Agreement, Eevia will benefit from the Partner's extensive market reach and strong sales force. The expectations from Eevia are for interesting but not dramatic revenue growth, but also for a more stable forecasting and growth of the global demand for this item.
"This partnership offers a global sales reach, with growth potential for Eevia from 2025 onward. By outsourcing clinical studies, marketing and sales, Eevia can focus on supply chain and manufacturing while our partner is driving revenue growth," says Erik Eide, Commercial Director in Eevia Health.
This disclosure contains information that EEVIA HEALTH PLC must make public according to the EU Market Abuse Regulation (EU nr 596/2014). The information was initially submitted for publication through the contact person's agency on February 12, 2025, at 13:15 EST.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com or investor@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses global health challenges with bioactive compounds sustainably extracted from renewable plant materials. It focuses on the gut and related health, including kidney and urinary health.
Eevia Health is a manufacturer of 100% organically certified plant extracts. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.
As a pioneering company, Eevia is developing high-value food ingredients, blended solutions, and biomaterials that significantly benefit human health. Eevia Health operates a modern green-chemistry production facility in Finland with a short value chain and environmentally friendly carbon footprint. Eevia listed its shares at the Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA. To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth.